This attempt to litigate is confusing.
It does not appear that they are attempting to certify a class action on behalf of the patients and Insurance companies, claiming that they paid too much for the drug. Based on the scant information in the news article, they are attempting to certify a class action on behalf of Ariad investors. As the price of the drug increased, rather then decreased, Ariad investors did not sustain stock losses, but stock gains, so where are the damages?
I hope someone can explain why this is being considered
